Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Trichostatin A |
Synonyms | |
Therapy Description |
Trichostatin A (TSA) inhibits histone deacetylase (HDAC) activity, which may lead to decreased tumor cell proliferation and viability and reduced tumor growth (PMID: 11309348, PMID: 22158273, PMID: 32753022). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trichostatin A | TSA | HDAC Inhibitor 45 | Trichostatin A (TSA) inhibits histone deacetylase (HDAC) activity, which may lead to decreased tumor cell proliferation and viability and reduced tumor growth (PMID: 11309348, PMID: 22158273, PMID: 32753022). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | glioblastoma | resistant | Trichostatin A | Preclinical - Cell culture | Actionable | In a preclinical study, glioblastoma cells expressing IDH1 R132H were resistant to treatment with Trichostatin (TSA) in culture, demonstrating decreased apoptotic activity and increased cell viability (PMID: 31151327). | 31151327 |
RB1 loss | retinoblastoma | sensitive | Trichostatin A | Preclinical - Cell culture | Actionable | In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719). | 23498719 18483379 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03838926 | Phase I | Trichostatin A | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | Unknown status | USA | 0 |